Mark R. Albertini, MD close
Mark R. Albertini, MD

New Patients

Contact the Welcome Center for help choosing a new primary care doctor.

For Referring Physicians

How to refer a patient

Mark R. Albertini, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Mark Albertini is an associate professor (with tenure) of medicine at the University of Wisconsin (UW). Dr. Albertini is a nationally known melanoma researcher who has led treatment efforts for patients with metastatic melanoma at the University of Wisconsin Carbone Cancer Center since he joined the faculty in 1993. Dr. Albertini established the UW Carbone Cancer Center Comprehensive Melanoma Clinic in September 1994 and is the leader of the UW Carbone Cancer Center Melanoma Disease-Oriented working group. Dr. Albertini has been awarded the Professionalism Award by the UW Department of Medicine Housestaff and has been selected for listing by the Best Doctors in America organization. Dr. Albertini has also served as Chief of Oncology at the William S. Middleton Memorial Veterans Hospital since January 2003.


Medical Oncology

Melanoma Cancer


UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Medical Oncology
Fellowship University of Wisconsin Comprehensive Cancer Center, Madison, WI
Residency University of Wisconsin Hospital and Clinics, Madison, WI
Internship University of Wisconsin Hospital and Clinics, Madison, WI
Medical School University of Vermont College of Medicine, Burlington, VT

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

The overall goal of Dr. Mark Albertini's research program is to provide an understanding of the immunobiology of human malignant melanoma as a means to develop effective treatment and monitoring strategies for patients with this disease. This goal is pursued with clinical and laboratory studies involving melanoma patients and with preclinical model systems to direct subsequent clinical studies. Dr. Albertini has been a mentor for clinical trainees with an interest in the care of melanoma patients, and Dr. Albertini has provided focused melanoma translational laboratory training to predoctoral and postdoctoral trainees in his research laboratory. Dr. Albertini has been a member of the Melanoma Committee in the Eastern Cooperative Oncology Group since 1994.

PubMed Articles
Cho SY Huff DT Jeraj R Albertini MR FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Semin Nucl Med . 2020 Nov;50(6):518-531
[PubMed ID: 33059821]
Yang RK Kuznetsov IB Ranheim EA Wei JS Sindiri S Gryder BE Gangalapudi V Song YK Patel V Hank JA Zuleger C Erbe AK Morris ZS Quale R Kim K Albertini MR Khan J Sondel PM Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2. Clin Cancer Res . 2020 Jul 1;26(13):3296-3306
[PubMed ID: 32152202]
Tarhini AA Lee SJ Hodi FS Rao UNM Cohen GI Hamid O Hutchins LF Sosman JA Kluger HM Eroglu Z Koon HB Lawrence DP Kendra KL Minor DR Lee CB Albertini MR Flaherty LE Petrella TM Streicher H Sondak VK Kirkwood JM Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609. J Clin Oncol . 2020 Feb 20;38(6):567-575
[PubMed ID: 31880964]
Zuleger CL Newton MA Ma X Ong IM Pei Q Albertini MR Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients. Melanoma Res . 2020 Feb;30(1):52-61
[PubMed ID: 31135600]
Tarhini AA Lee SJ Li X Rao UNM Nagarajan A Albertini MR Mitchell JW Jr Wong SJ Taylor MA Laudi N Truong PV Conry RM Kirkwood JM E3611-A Randomized Phase II Study of Ipilimumab at 3 or 10 mg/kg Alone or in Combination with High-Dose Interferon-α2b in Advanced Melanoma. Clin Cancer Res . 2019 Jan 15;25(2):524-532
[PubMed ID: 30420448]
Jeter JM Bowles TL Curiel-Lewandrowski C Swetter SM Filipp FV Abdel-Malek ZA Geskin LJ Brewer JD Arbiser JL Gershenwald JE Chu EY Kirkwood JM Box NF Funchain P Fisher DE Kendra KL Marghoob AA Chen SC Ming ME Albertini MR Vetto JT Margolin KA Pagoto SL Hay JL Grossman D Ellis DL Kashani-Sabet M Mangold AR Markovic SN Meyskens FL Jr Nelson KC Powers JG Robinson JK Sahni D Sekulic A Sondak VK Wei ML Zager JS Dellavalle RP Thompson JA Weinstock MA Leachman SA Cassidy PB Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer . 2019 Jan 1;125(1):18-44
[PubMed ID: 30281145]
Albertini MR Yang RK Ranheim EA Hank JA Zuleger CL Weber S Neuman H Hartig G Weigel T Mahvi D Henry MB Quale R McFarland T Gan J Carmichael L Kim K Loibner H Gillies SD Sondel PM Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma. Cancer Immunol Immunother . 2018 Oct;67(10):1647-1658
[PubMed ID: 30073390]
Albertini MR The age of enlightenment in melanoma immunotherapy. J Immunother Cancer . 2018 Aug 22;6(1):80
[PubMed ID: 30134977]
Kim T Havighurst T Kim K Albertini M Xu YG Spiegelman VS Targeting insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in metastatic melanoma to increase efficacy of BRAF<sup>V600E</sup> inhibitors. Mol Carcinog . 2018 May;57(5):678-683
[PubMed ID: 29369405]
Agarwala SS Lee SJ Yip W Rao UN Tarhini AA Cohen GI Reintgen DS Evans TL Brell JM Albertini MR Atkins MB Dakhil SR Conry RM Sosman JA Flaherty LE Sondak VK Carson WE Smylie MG Pappo AS Kefford RF Kirkwood JM Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). J Clin Oncol . 2017 Mar 10;35(8):885-892
[PubMed ID: 28135150]
Atkinson TM Hay JL Shoushtari A Li Y Paucar DJ Smith SC Kudchadkar RR Doyle A Sosman JA Quevedo JF Milhem MM Joshua AM Linette GP Gajewski TF Lutzky J Lawson DH Lao CD Flynn PJ Albertini MR Sato T Lewis K Marr B Abramson DH Dickson MA Schwartz GK Carvajal RD Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol . 2017 Mar;143(3):439-445
[PubMed ID: 27921276]
Albertini MR Ranheim EA Zuleger CL Sondel PM Hank JA Bridges A Newton MA McFarland T Collins J Clements E Henry MB Neuman HB Weber S Whalen G Galili U Phase I study to evaluate toxicity and feasibility of intratumoral injection of α-gal glycolipids in patients with advanced melanoma. Cancer Immunol Immunother . 2016 Aug;65(8):897-907
[PubMed ID: 27207605]
Wisinski KB Ledesma WM Kolesar J Wilding G Liu G Douglas J Traynor AM Albertini M Mulkerin D Bailey HH A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract . 2015 Dec;21(6):416-24
[PubMed ID: 24986793]
Carvajal RD Sosman JA Quevedo JF Milhem MM Joshua AM Kudchadkar RR Linette GP Gajewski TF Lutzky J Lawson DH Lao CD Flynn PJ Albertini MR Sato T Lewis K Doyle A Ancell K Panageas KS Bluth M Hedvat C Erinjeri J Ambrosini G Marr B Abramson DH Dickson MA Wolchok JD Chapman PB Schwartz GK Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. JAMA . 2014 Jun 18;311(23):2397-405
[PubMed ID: 24938562]
Pei Q Zuleger CL Macklin MD Albertini MR Newton MA A conditional predictive p-value to compare a multinomial with an overdispersed multinomial in the analysis of T-cell populations. Biostatistics . 2014 Jan;15(1):129-39
[PubMed ID: 24096387]
Bhatia N Xiao TZ Rosenthal KA Siddiqui IA Thiyagarajan S Smart B Meng Q Zuleger CL Mukhtar H Kenney SC Albertini MR Jack Longley B MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Invest Dermatol . 2013 Mar;133(3):759-767
[PubMed ID: 23096706]
Albertini MR Hank JA Gadbaw B Kostlevy J Haldeman J Schalch H Gan J Kim K Eickhoff J Gillies SD Sondel PM Phase II trial of hu14.18-IL2 for patients with metastatic melanoma. Cancer Immunol Immunother . 2012 Dec;61(12):2261-71
[PubMed ID: 22678096]
Zuleger CL Albertini MR OMIP-008: measurement of Th1 and Th2 cytokine polyfunctionality of human T cells. Cytometry A . 2012 Jun;81(6):450-2
[PubMed ID: 22431369]
Hank JA Gan J Ryu H Ostendorf A Stauder MC Sternberg A Albertini M Lo KM Gillies SD Eickhoff J Sondel PM Immunogenicity of the hu14.18-IL2 immunocytokine molecule in adults with melanoma and children with neuroblastoma. Clin Cancer Res . 2009 Sep 15;15(18):5923-30
[PubMed ID: 19737959]
Yamane BH Hank JA Albertini MR Sondel PM The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs . 2009 Jul;18(7):991-1000
[PubMed ID: 19548853]